Change of therapy occurred in over 37% of patients, with the majority moving away from chemotherapy treatment.

“In over one third (37.7%) the results of the EndoPredict assay lead to a change of planned therapy. For a quarter of patients (25.4%) the originally planned chemotherapy could be omitted based on the result of the multi-gene assay.”

Müller BM, Keil E, Lehmann A, et al. The EndoPredict gene-expression assay in clinical practice – performance and impact on clinical decisions. PLoS One. 2013;8(6):e68252.

Learn More View Article